LATEST NEWS
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
How much ‘green’ is cancer research?
Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Health as a human right, cancer care as a human priority
Universal health coverage in oncology is still not a reality, as a recent report shows
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
ROAD TO ESMO GASTROINTESTINAL CANCERS CONGRESS 2024
Extending the continuum of care for metastatic colorectal cancer
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients